Researchers have unveiled a promising hormone, FGF21 (fibroblast growth factor 21), which shows potential in combating obesity. This hormone has garnered interest as a possible target for innovative therapies, with clinical trials already underway for drugs aimed at MASH (metabolic dysfunction-associated steatohepatitis), a severe form of fatty liver disease.
Dr. Matthew Potthoff, the lead investigator, and his team have delved into the mechanisms by which FGF21 exerts its effects. Their findings indicate that the hormone operates through the hindbrain, located at the lower back of the brain.
Surprising Discovery in Brain Function
"In our earlier research, we established that FGF21 communicates with the brain rather than the liver, but the specific brain region was unknown," explained Potthoff, who serves as a professor of biochemistry and physiology at the OU College of Medicine and deputy director of the OU Health Harold Hamm Diabetes Center. "We anticipated that it would signal to the hypothalamus, a key player in weight regulation, so discovering its connection to the hindbrain was unexpected."
FGF21 specifically interacts with two areas of the hindbrain: the nucleus of the solitary tract (NTS) and the area postrema (AP). These regions subsequently relay information to another structure known as the parabrachial nucleus. This signaling pathway is crucial for the hormone's role in metabolism and weight reduction.
Brain Circuit Enhances Fat Burning
"This brain circuit appears to mediate the effects of FGF21," Potthoff noted. "By pinpointing this specific circuit, we aim to develop more targeted therapies that minimize adverse effects. Current FGF21 analogues can lead to gastrointestinal issues and, in some cases, bone density loss."
While FGF21 and GLP-1 medications target similar brain regions, their mechanisms differ significantly. GLP-1 drugs focus on reducing appetite and food consumption, whereas FGF21 enhances metabolic activity, promoting energy expenditure and weight loss.
Future Prospects for Obesity and Liver Disease Treatments
Potthoff and his team are optimistic that their research could pave the way for novel treatments for obesity and MASH. "Although this study concentrated on FGF21's mechanism for weight reduction, further research is essential to determine whether this circuit also plays a role in the hormone's potential to reverse MASH," he added.
